Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System

Inclusion criteria for breast cancer patients (Arm 1):

• Women aged ≥ 18 years;

• Brazilian nationality;

• After review at the Hospital Moinhos de Vento, confirmed histological diagnosis of breast carcinoma with overexpression of HER2 (classified by immunohistochemistry as 3+ or 2+ with positive in-situ hybridization) or triple-negative (estrogen and progesterone receptors <1% and no overexpression of HER2);

• Clinical stage II or III for HER2-positive and I, II and III for triple-negative patients - American Joint Committee on Cancer (AJCC) 8th edition;

• HER2- positive patients: must undergo neoadjuvant chemotherapy plus trastuzumab in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel), combined with trastuzumab, or a non-anthracycline option consisting of taxane (docetaxel or paclitaxel) combined with carboplatin and trastuzumab;

• Triple-negative patients: must undergo neoadjuvant chemotherapy without immunotherapy in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel) with/ without platins (carboplatin ou cisplatin) or a regimen without anthracycline (taxane with/without platins)

• Patients must provide written informed consent prior to inclusion

Inclusion criteria for patients with prostate cancer (Arm 2):

• Men aged ≥ 18 years;

• Confirmed histological diagnosis of prostate adenocarcinoma;

• AJCC 8th edition clinical stage IV;

• Patients must provide written informed consent.

Exclusion criteria for Arms 1 and 2:

• No available paraffin-embedded tumor tissue for genomic analysis;

• Inability to collect blood for genomic evaluation.